Mechanisms and Refinements of PSCA Directed Antibody Therapy

Abstract

Prostate cancer is the second leading cause of cancer-related death in American men. New treatments are needed. Prostate stem cell antigen (PSCA) is a cell surface protein over expressed by a 40% of localized and as many as 80-100% of metastatic prostate cancers. A monoclonal antibody generated in our lab against PSCA inhibits growth and metastasis of prostate cancer in animal models, but the mechanism of action is not known. The goals of this grant are (1) to determine the mechanism of therapeutic activity monoclonal antibodies against PSCA and (2) to enhance the activity of these antibodies using combination approaches.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 01, 2004
Accession Number
ADA426030

Entities

People

  • Robert E. Reiter

Organizations

  • University of California, Los Angeles

Tags

DTIC Thesaurus Topics

  • Anatomy
  • Antibodies
  • Antigens
  • Biological Sciences
  • Biomedical Research
  • California
  • Cancer
  • Cell Physiological Processes
  • Cells
  • Drug Combinations
  • Immune System
  • Metastasis
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Stem Cells
  • Therapy

Fields of Study

  • Biology

Readers

  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech